DOP2020000148A - Inhibidores de cd73 - Google Patents
Inhibidores de cd73Info
- Publication number
- DOP2020000148A DOP2020000148A DO2020000148A DO2020000148A DOP2020000148A DO P2020000148 A DOP2020000148 A DO P2020000148A DO 2020000148 A DO2020000148 A DO 2020000148A DO 2020000148 A DO2020000148 A DO 2020000148A DO P2020000148 A DOP2020000148 A DO P2020000148A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- inhibitors
- pyridazin
- dione
- pyrimidine
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862636978P | 2018-03-01 | 2018-03-01 | |
| US201862775553P | 2018-12-05 | 2018-12-05 | |
| PCT/US2019/019074 WO2019168744A1 (en) | 2018-03-01 | 2019-02-22 | Cd73 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2020000148A true DOP2020000148A (es) | 2020-09-15 |
Family
ID=65686120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2020000148A DOP2020000148A (es) | 2018-03-01 | 2020-07-28 | Inhibidores de cd73 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US11028074B2 (lt) |
| EP (1) | EP3759096B1 (lt) |
| JP (1) | JP6794560B2 (lt) |
| KR (1) | KR20200116965A (lt) |
| CN (1) | CN111819173B (lt) |
| AU (1) | AU2019228473B2 (lt) |
| BR (1) | BR112020016066A2 (lt) |
| CA (1) | CA3092661C (lt) |
| CL (1) | CL2020002158A1 (lt) |
| CO (1) | CO2020010191A2 (lt) |
| CR (1) | CR20200376A (lt) |
| CY (1) | CY1125145T1 (lt) |
| DK (1) | DK3759096T3 (lt) |
| DO (1) | DOP2020000148A (lt) |
| EC (1) | ECSP20052897A (lt) |
| ES (1) | ES2909701T3 (lt) |
| HR (1) | HRP20220459T1 (lt) |
| IL (1) | IL277006B2 (lt) |
| JO (1) | JOP20200209A1 (lt) |
| LT (1) | LT3759096T (lt) |
| MA (1) | MA52413A (lt) |
| MX (1) | MX2020009115A (lt) |
| PE (1) | PE20210177A1 (lt) |
| PH (1) | PH12020551464A1 (lt) |
| PL (1) | PL3759096T3 (lt) |
| PT (1) | PT3759096T (lt) |
| RS (1) | RS63073B1 (lt) |
| SG (1) | SG11202008366RA (lt) |
| SI (1) | SI3759096T1 (lt) |
| TW (1) | TWI702954B (lt) |
| UA (1) | UA123890C2 (lt) |
| WO (1) | WO2019168744A1 (lt) |
| ZA (1) | ZA202004805B (lt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7292501B2 (ja) * | 2019-08-29 | 2023-06-16 | イーライ リリー アンド カンパニー | Ｃｄ７３阻害剤の結晶形態 |
| WO2021113625A1 (en) * | 2019-12-06 | 2021-06-10 | Plexxikon Inc. | Compounds and methods for cd73 modulation and indications therefor |
| JP2023522949A (ja) * | 2020-04-23 | 2023-06-01 | オプナ バイオ ソシエテ アノニム | Ｃｄ７３調節のための化合物及び方法並びにそれらの表示 |
| US12110294B2 (en) * | 2020-05-01 | 2024-10-08 | Gilead Sciences, Inc. | CD73 compounds |
| CN115702150A (zh) * | 2020-07-07 | 2023-02-14 | 贝达药业股份有限公司 | Cd73抑制剂及其在医药上的应用 |
| CA3191829A1 (en) | 2020-09-08 | 2022-03-17 | Hao Wu | Cd73 inhibitor and application thereof in medicine |
| WO2022068929A1 (zh) * | 2020-09-30 | 2022-04-07 | 武汉人福创新药物研发中心有限公司 | 嘧啶二酮类化合物及其用途 |
| WO2022090711A1 (en) | 2020-10-26 | 2022-05-05 | AdoRx Therapeutics Limited | Compounds as cd73 inhibitors |
| CN114437039A (zh) | 2020-11-05 | 2022-05-06 | 武汉人福创新药物研发中心有限公司 | Cd73抑制剂及其应用 |
| CN114437038A (zh) * | 2020-11-05 | 2022-05-06 | 武汉人福创新药物研发中心有限公司 | 哒嗪炔烃类化合物及其用途 |
| CN116134029A (zh) * | 2020-12-10 | 2023-05-16 | 上海翰森生物医药科技有限公司 | 氧代氮环类衍生物调节剂、其制备方法和应用 |
| WO2022195499A1 (en) * | 2021-03-19 | 2022-09-22 | Aurigene Discovery Technologies Limited | Substituted pyridazine compounds as cd73 inhibitors |
| MX2024005066A (es) | 2021-10-29 | 2024-05-24 | Gilead Sciences Inc | Compuestos de cd73. |
| WO2023169327A1 (zh) * | 2022-03-07 | 2023-09-14 | 贝达药业股份有限公司 | 一种哒嗪类衍生物的晶型、制备方法及其应用 |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| US20240116928A1 (en) * | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024013206A1 (en) * | 2022-07-14 | 2024-01-18 | F. Hoffmann-La Roche Ag | Heterocycle compounds for the treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20071152A1 (es) | 2006-04-03 | 2007-12-16 | Glaxo Group Ltd | Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3 |
| EP1860113A1 (en) | 2006-05-24 | 2007-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Ectonucleotidase inhibitors |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| KR20180100638A (ko) * | 2016-01-08 | 2018-09-11 | 아르커스 바이오사이언시즈 인코포레이티드 | 5'-뉴클레오티다아제, 엑토의 조절제, 및 이의 용도 |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
-
2019
- 2019-02-15 TW TW108105130A patent/TWI702954B/zh not_active IP Right Cessation
- 2019-02-22 SI SI201930184T patent/SI3759096T1/sl unknown
- 2019-02-22 CA CA3092661A patent/CA3092661C/en active Active
- 2019-02-22 WO PCT/US2019/019074 patent/WO2019168744A1/en active Application Filing
- 2019-02-22 BR BR112020016066-0A patent/BR112020016066A2/pt not_active IP Right Cessation
- 2019-02-22 ES ES19709335T patent/ES2909701T3/es active Active
- 2019-02-22 AU AU2019228473A patent/AU2019228473B2/en not_active Ceased
- 2019-02-22 PL PL19709335T patent/PL3759096T3/pl unknown
- 2019-02-22 SG SG11202008366RA patent/SG11202008366RA/en unknown
- 2019-02-22 JP JP2019557361A patent/JP6794560B2/ja active Active
- 2019-02-22 UA UAA202005110A patent/UA123890C2/uk unknown
- 2019-02-22 RS RS20220310A patent/RS63073B1/sr unknown
- 2019-02-22 CN CN201980016287.8A patent/CN111819173B/zh active Active
- 2019-02-22 LT LTEPPCT/US2019/019074T patent/LT3759096T/lt unknown
- 2019-02-22 IL IL277006A patent/IL277006B2/en unknown
- 2019-02-22 DK DK19709335.4T patent/DK3759096T3/da active
- 2019-02-22 KR KR1020207025071A patent/KR20200116965A/ko active IP Right Grant
- 2019-02-22 CR CR20200376A patent/CR20200376A/es unknown
- 2019-02-22 PT PT197093354T patent/PT3759096T/pt unknown
- 2019-02-22 JO JOP/2020/0209A patent/JOP20200209A1/ar unknown
- 2019-02-22 US US16/481,146 patent/US11028074B2/en active Active
- 2019-02-22 HR HRP20220459TT patent/HRP20220459T1/hr unknown
- 2019-02-22 PE PE2020001302A patent/PE20210177A1/es unknown
- 2019-02-22 EP EP19709335.4A patent/EP3759096B1/en active Active
- 2019-02-22 MA MA052413A patent/MA52413A/fr unknown
- 2019-02-22 MX MX2020009115A patent/MX2020009115A/es unknown
-
2020
- 2020-07-28 DO DO2020000148A patent/DOP2020000148A/es unknown
- 2020-08-03 ZA ZA2020/04805A patent/ZA202004805B/en unknown
- 2020-08-19 CO CONC2020/0010191A patent/CO2020010191A2/es unknown
- 2020-08-21 CL CL2020002158A patent/CL2020002158A1/es unknown
- 2020-08-31 EC ECSENADI202052897A patent/ECSP20052897A/es unknown
- 2020-09-01 PH PH12020551464A patent/PH12020551464A1/en unknown
-
2022
- 2022-04-12 CY CY20221100276T patent/CY1125145T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20052897A (es) | Inhibidores de cd73 | |
| ECSP19033052A (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| ECSP19032676A (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
| CL2018001753A1 (es) | Composiciones para modular la expresión de c9orf72 (divisional solicitud 201600839) | |
| EA201990202A1 (ru) | Ингибиторы диацилглицеринацилтрансферазы 2 | |
| CL2017001362A1 (es) | Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática | |
| UY35834A (es) | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon | |
| CL2018002698A1 (es) | Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a | |
| EA201790170A1 (ru) | Терапевтические соединения-ингибиторы | |
| CO2018006097A2 (es) | Pesticidas azoles bicíclicos sustituídos con heterociclo | |
| MX2020003868A (es) | Compuesto heterociclico como inhibidor de proteina quinasa. | |
| CL2019002854A1 (es) | Compuesto macrocíclico y sus usos. | |
| CL2017001209A1 (es) | Inhibidor de cinasa aurora a | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| WO2016198698A3 (en) | P38 inhibitors for the treatment and prophylaxis of liver cancer | |
| ZA202003281B (en) | Heterocycle substituted pyridine derivative antifungal agents | |
| CO2017009182A2 (es) | Cepas bacterianas productoras de histamina para tratamiento del cáncer | |
| CO2021008535A2 (es) | Compuestos de quinolina como inhibidores de quinasas tam y met | |
| SV2018005701A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| CL2016003271A1 (es) | Métodos para tratar infecciones | |
| EA202091821A1 (ru) | Ингибиторы cd73 | |
| CL2019001046A1 (es) | Terapia de combinación que incluye un inhibidor mdm2 y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cáncer. (divisional solicitud 201601131) | |
| MA53225A (fr) | Agents inhibiteurs d'ask1 |